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Background: Treatment with primary percutaneous coronary intervention (PPCI) is most beneficial in high-risk myocardial infarction (MI) patients. 
Elderly patients have been a focus of study, including small randomized trials, of reperfusion strategy since they are both high risk for death as well 
as complications from both procedures and fibrinolytic therapy. We evaluated the clinical effects of PPCI in relation to age.
Methods: Twenty-five randomized trials (n=7743) that evaluated the efficacy and safety of PPCI vs. FL were identified in journal articles and 
abstract listings published between 1990 and 2002. Individual patient data were obtained from 22 trials (n=6763). Differences in 30-day death, 
repeat myocardial infarction (reMI) and stroke between patients randomized to FL and PPCI were determined in 5 strata according to age: =<50, 
>50-60, >60-70, >70-80, and >80 years. Breslow-Day tests and multivariable logistic regression (LR) analyses were applied to examine evidence of 
heterogeneity in age-specific Odds ratios (OR)s.
Results: Thirty-day death markedly increased with increasing age, and ranged from 1.1% (FL) and 1.8% (PPCI) in patients =<50 years to 26.4% and 
18.3% in patients >80 years, respectively. The point estimate of treatment effect (overall adjusted OR 0.65 and 95% CI 0.52-0.79) was compatible 
with a mortality reduction favoring PPCI in all age-strata (except in patients =<50 years), and 95% CIs were largely overlapping. There was no 
evidence of heterogeneity in ORs between age categories (Breslow-Day p-value 0.24). Similar results were observed with respect to reMI and stroke.
Conclusion: In this pooled analysis of randomized clinical trials, the relative reduction in clinical endpoints by PPCI was not influenced by age, 
although absolute benefits were greater in the elderly. Hence, irrespective of age, primary PCI is the preferred strategy, and is of particular benefit in 
the elderly.
